| Symbol | TYRA |
|---|---|
| Name | TYRA BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2656 STATE STREET, CARLSBAD, California, 92008, United States |
| Telephone | +1 619 728-4760 |
| Fax | — |
| — | |
| Website | https://www.tyra.bio |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001863127 |
| Description | Tyra Biosciences Inc is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Additional info from NASDAQ: |
2026-08-14 17:45
New Form SCHEDULE 13G/A - Tyra Biosciences, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001804218-26-000003 <b>Size:</b> 14 KB
Read more
2026-08-14 09:25
New Form SCHEDULE 13G/A - Tyra Biosciences, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000908834-26-000427 <b>Size:</b> 47 KB
Read more
2026-08-04 20:07
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
Read more
2026-06-26 20:59
📋 NEXTECH VI ONCOLOGY SCSP (Shareholder) plans to sell 308K shares of TYRA BIOSCIENCES, INC. (at $30.94 each, total $9.5M) Filed: Jun 26, 2026 | ID: 045813
Read more
2026-06-01 21:45
RA CAPITAL MANAGEMENT, L.P. 🟢 acquired 13.2K shares (1 derivative) of Tyra Biosciences, Inc. (TYRA) at $32.68 Transaction Date: May 28, 2026 | Filing ID: 000590
Read more
2026-06-01 20:30
Gulfo Adele M. 🟢 acquired 13.2K shares (1 derivative) of Tyra Biosciences, Inc. (TYRA) at $32.68 Transaction Date: May 28, 2026 | Filing ID: 251536
Read more
2026-06-01 20:30
MORE ROBERT J 🟢 acquired 13.2K shares (1 derivative) of Tyra Biosciences, Inc. (TYRA) at $32.68 Transaction Date: May 28, 2026 | Filing ID: 251534
Read more
2026-06-01 20:30
Rothenberg Stephen Michael 🟢 acquired 13.2K shares (1 derivative) of Tyra Biosciences, Inc. (TYRA) at $32.68 Transaction Date: May 28, 2026 | Filing ID: 251532
Read more
2026-06-01 20:16
📋 NEXTECH VI ONCOLOGY SCSP (Shareholder) plans to sell 300K shares of TYRA BIOSCIENCES, INC. (at $33.41 each, total $10.0M) Filed: Jun 01, 2026 | ID: 039506
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07265947 | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade U… | Phase2 | Low Grade Upper Tract Urothelial Carcinoma | Recruiting | 2025-12-22 | 2030-11-01 | ClinicalTrials.gov |
| NCT06995677 | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, I… | Phase2 | Low-grade NMIBC | Recruiting | 2025-06-27 | 2028-09-01 | ClinicalTrials.gov |
| NCT06915753 | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellul… | Phase1 | Metastatic Hepatocellular Carcinoma | Recruiting | 2025-04-24 | 2028-09-01 | ClinicalTrials.gov |
| NCT06842355 | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 | Phase2 | Achondroplasia | Recruiting | 2025-03-04 | 2030-06-01 | ClinicalTrials.gov |
| NCT06160752 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With … | Phase1 | Locally Advanced Cholangiocarcinoma | Active_Not_Recruiting | 2023-11-22 | 2027-09-01 | ClinicalTrials.gov |
| NCT06006702 | A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Ta… | Phase1 | Healthy | Active_Not_Recruiting | 2023-10-16 | 2025-07-01 | ClinicalTrials.gov |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial C… | Phase1 | Locally Advanced Urothelial Carcinoma | Active_Not_Recruiting | 2022-11-22 | 2027-06-01 | ClinicalTrials.gov |
Total clinical trials: 7
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| TYRA-300 0.625 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.625 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | Other | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT06160752 |
| Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles | Other | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | ACTIVE_NOT_RECRUITING | NCT06160752 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-430 | Other | Phase PHASE1 | Metastatic Hepatocellular Carcinoma | RECRUITING | NCT06915753 |
| Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | Other | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | RECRUITING | NCT06160752 |
| Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles | Other | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | RECRUITING | NCT06160752 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | Other | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | RECRUITING | NCT06160752 |
| Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles | Other | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | RECRUITING | NCT06160752 |
| TYRA-300-B01 | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06006702 |
| TYRA-430 | Other | Phase PHASE1 | Metastatic Hepatocellular Carcinoma | RECRUITING | NCT06915753 |
| TYRA-300 | Other | Phase PHASE1 | Locally Advanced Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05544552 |
| Dabogratinib (TYRA-300) TBD | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | Other | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 Dose TBD | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | Other | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.50 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| Dabogratinib (TYRA-300) TBD | DRUG | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 80mg | DRUG | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| Dabogratinib (TYRA-300) 60mg | DRUG | Phase PHASE2 | Low Grade Upper Tract Urothelial Carcinoma | RECRUITING | NCT07265947 |
| TYRA-300 Dose TBD | DRUG | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 50mg | DRUG | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-300 60mg | DRUG | Phase PHASE2 | Low-grade NMIBC | RECRUITING | NCT06995677 |
| TYRA-430 | DRUG | Phase PHASE1 | Metastatic Hepatocellular Carcinoma | RECRUITING | NCT06915753 |
| TYRA-300 0.50 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.375 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.25 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| TYRA-300 0.125 mg/kg | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06842355 |
| Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles | DRUG | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | RECRUITING | NCT06160752 |
| Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles | DRUG | Phase PHASE1 | Locally Advanced Cholangiocarcinoma | RECRUITING | NCT06160752 |
| TYRA-300-B01 | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06006702 |
| TYRA-300 | DRUG | Phase PHASE1 | Locally Advanced Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05544552 |
Total products: 436